Total Synthesis of 6-Deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 Cancer Cell Line
Kenzo Arai,Silvia Buonamici,Betty Chan,Laura Corson,Atsushi Endo,Baudouin Gerard,Ming-Hong Hao,Craig Karr,Kazunobu Kira,Linda Lee,Xiang Liu,Jason T Lowe,Tuoping Luo,Lisa A Marcaurelle,Yoshiharu Mizui,Marta Nevalainen,Morgan Welzel O'Shea,Eun Sun Park,Samantha A Perino,Sudeep Prajapati,Mingde Shan,Peter G Smith,Parcharee Tivitmahaisoon,John Yuan Wang,Markus Warmuth,Kuo-Ming Wu,Lihua Yu,Huiming Zhang,Guo-Zhu Zheng,Gregg F Keaney
DOI: https://doi.org/10.1021/ol502556c
IF: 5.2
2014-01-01
Organic Letters
Abstract:A total synthesis of the natural product 6-deoxypladienolide D (1) has been achieved. Two noteworthy attributes of the synthesis are (1) a late-stage allylic oxidation which proceeds with full chemo-, regio-, and diastereoselectivity and (2) the development of a scalable and cost-effective synthetic route to support drug discovery efforts. 6-Deoxypladienolide D (1) demonstrates potent growth inhibition in a mutant SF3B1 cancer cell line, high binding affinity to the SF3b complex, and inhibition of pre-mRNA splicing.